LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

• Market Cap: €202.54M
• Dividend Yield: 1.91%
• Average Volume (3M): 44.99K
• Price to Earnings (P/E): 41.7
• Beta (1Y): 0.27
• Revenue Growth: -1.19%
• EPS Growth: -54.66%
• Country: ES
• Employees: 1,331
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 82,219,240
• 10 Day Avg. Volume: 48,066
• 30 Day Avg. Volume: 44,988
• PEG Ratio: -0.79
• Price to Book (P/B): 0.96
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -15.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.15
• Revenue Forecast (FY): €349.90M

• Rating: 46 Neutral
• Price Target: €2.50 ▼(-6.72% Downside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is weighed down primarily by the 2025 financial setback—sharp revenue decline, heavily compressed margins, and a swing to negative free cash flow—alongside increased leverage. Technicals add further pressure with a clear downtrend and negative momentum. Valuation is also a headwind due to a high P/E, only partly offset by a modest dividend yield.

Positive Factors

Diversified revenue model and partnerships

A diversified commercial mix—direct sales to providers, pharmacies and hospitals plus partnerships and licensing—reduces single-market concentration. Strategic collaborations and licensing create durable channels for product distribution, technology access and potential royalty streams over the medium term.

Negative Factors

2025 sharp revenue contraction

A ~20% revenue decline in 2025 materially reduces scale and breaks operating leverage, pressuring margins and net income. Such a large single-year drop may reflect structural demand loss, competitive displacement, or product issues that could take multiple quarters to correct and hamper long-term recovery.

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products inc...

Read more

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products inc...

How the Company Makes Money

Laboratorio Reig Jofre generates revenue primarily through the sale of pharmaceutical products, which includes both prescription medications and over-the-counter drugs. The company has a diversified revenue model that incorporates direct sales to ...

Read more

Laboratorio Reig Jofre generates revenue primarily through the sale of pharmaceutical products, which includes both prescription medications and over-the-counter drugs. The company has a diversified revenue model that incorporates direct sales to ...

LABORATORIO REIG JOFRE Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	415.66M	331.10M	338.89M	316.09M	271.15M	236.23M
Gross Profit	244.01M	81.71M	195.68M	176.89M	69.58M	144.98M
EBITDA	38.46M	30.48M	36.18M	33.89M	30.44M	24.66M
Net Income	8.86M	5.02M	10.38M	9.41M	8.11M	5.09M
Balance Sheet
Total Assets	357.56M	396.56M	344.85M	330.55M	321.19M	324.98M
Cash, Cash Equivalents and Short-Term Investments	10.84M	16.84M	16.08M	6.36M	6.88M	5.16M
Total Debt	67.06M	98.53M	58.52M	53.49M	61.24M	67.38M
Total Liabilities	141.17M	170.24M	130.90M	126.29M	126.64M	136.46M
Stockholders Equity	216.42M	218.07M	213.97M	204.35M	194.63M	188.59M
Cash Flow
Free Cash Flow	0.00	-13.78M	10.56M	6.34M	4.75M	-5.26M
Operating Cash Flow	0.00	1.51M	31.34M	19.11M	16.15M	14.50M
Investing Cash Flow	0.00	-17.82M	-31.96M	-12.88M	-12.72M	-34.70M
Financing Cash Flow	0.00	16.31M	5.59M	-7.16M	-2.04M	13.67M

LABORATORIO REIG JOFRE Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Neutral. The current price of 2.68 is above the 20-day moving average (MA) of 2.44, above the 50-day MA of 2.57, and below the 200-day MA of 2.79, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 36.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	73 Outperform	€4.18B	23.13	23.03%	1.50%	-9.39%	-25.92%
CBAV	67 Neutral	€780.94M	15.29	45.95%	3.31%	―	―
ALM	59 Neutral	€2.65B	35.12	3.96%	1.22%	13.32%	―
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
GRF	53 Neutral	€5.71B	18.75	7.56%	1.37%	7.31%	158.58%
FAE	51 Neutral	€1.46B	20.17	18.13%	3.51%	11.04%	8.29%
RJF	46 Neutral	€202.54M	41.66	2.03%	1.91%	-1.19%	-54.66%